The category of T-cell therapy, which revolutionized the management of specific blood cancers, has now extended its impact to solid tumor treatment with the approval from the FDA of a groundbreaking immunotherapy pioneered by Iovance Biotherapeutics. Known as Amtagvi or lifileucel, this medication marks the debut of personalized tumor-infiltrating lymphocyte (TIL) therapy in the market.
WuXi Advanced Therapies, a company fully owned by WuXi AppTec, has revealed that its Philadelphia facility has gained approval from the FDA to commence analytical testing and manufacturing of Amtagvi for Iovance. This follows Iovance’s receipt of FDA accelerated approval for its Bio...
